These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35560226)

  • 1. Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory Depression.
    Abuhelwa AY; Somogyi AA; Loo CK; Glue P; Barratt DT; Foster DJR
    Clin Pharmacol Ther; 2022 Sep; 112(3):720-729. PubMed ID: 35560226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the norketamine metabolite in children and the implications for analgesia.
    Herd DW; Anderson BJ; Holford NH
    Paediatr Anaesth; 2007 Sep; 17(9):831-40. PubMed ID: 17683400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series.
    Tham JCW; Do A; Fridfinnson J; Rafizadeh R; Siu JTP; Budd GP; Lam RW
    Int Clin Psychopharmacol; 2022 Sep; 37(5):206-214. PubMed ID: 35695279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
    Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
    Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.
    Fanta S; Kinnunen M; Backman JT; Kalso E
    Eur J Clin Pharmacol; 2015 Apr; 71(4):441-7. PubMed ID: 25724645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression.
    Lai R; Katalinic N; Glue P; Somogyi AA; Mitchell PB; Leyden J; Harper S; Loo CK
    World J Biol Psychiatry; 2014 Sep; 15(7):579-84. PubMed ID: 24910102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
    Correia-Melo FS; Leal GC; Vieira F; Jesus-Nunes AP; Mello RP; Magnavita G; Caliman-Fontes AT; Echegaray MVF; Bandeira ID; Silva SS; Cavalcanti DE; Araújo-de-Freitas L; Sarin LM; Tuena MA; Nakahira C; Sampaio AS; Del-Porto JA; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    J Affect Disord; 2020 Mar; 264():527-534. PubMed ID: 31786030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures.
    Brunette KE; Anderson BJ; Thomas J; Wiesner L; Herd DW; Schulein S
    Paediatr Anaesth; 2011 Jun; 21(6):653-62. PubMed ID: 21355949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective pharmacokinetics of ketamine and norketamine after racemic ketamine or S-ketamine administration during isoflurane anaesthesia in Shetland ponies.
    Larenza MP; Landoni MF; Levionnois OL; Knobloch M; Kronen PW; Theurillat R; Schatzmann U; Thormann W
    Br J Anaesth; 2007 Feb; 98(2):204-12. PubMed ID: 17218377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.
    Moaddel R; Luckenbaugh DA; Xie Y; Villaseñor A; Brutsche NE; Machado-Vieira R; Ramamoorthy A; Lorenzo MP; Garcia A; Bernier M; Torjman MC; Barbas C; Zarate CA; Wainer IW
    Psychopharmacology (Berl); 2015 Jan; 232(2):399-409. PubMed ID: 25056852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal volume and the rapid antidepressant effect of ketamine.
    Abdallah CG; Salas R; Jackowski A; Baldwin P; Sato JR; Mathew SJ
    J Psychopharmacol; 2015 May; 29(5):591-5. PubMed ID: 25122038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents.
    Chidambaran V; Venkatasubramanian R; Sadhasivam S; Esslinger H; Cox S; Diepstraten J; Fukuda T; Inge T; Knibbe CAJ; Vinks AA
    Paediatr Anaesth; 2015 Sep; 25(9):911-923. PubMed ID: 25975390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
    Larkin GL; Beautrais AL
    Int J Neuropsychopharmacol; 2011 Sep; 14(8):1127-31. PubMed ID: 21557878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.